Icagen halts trial enrollment on adverse event; GenVec gets milestone payment from Novartis;

@FierceBiotech: FDA takes second look at meta-analysis. Report | Follow @FierceBiotech

@JohnCFierce: Wrapping choices on this year's Fierce 15. Good group of companies. Rusty IPO window gives me plenty of companies to choose from | Follow @FierceBiotech

> Icagen has suspended further enrollment in the epilepsy study of ICA-105665 following the occurrence of a serious adverse event. The SAE occurred in the 600mg patient cohort following completion of the 500mg patient cohort. Icagen will be discussing the status of the study with its clinical advisors and with the FDA. Icagen release

> GenVec has achieved the first milestone in its collaboration with Novartis related to the development of treatments for hearing loss and balance disorders. The milestone was triggered by the successful completion of certain preclinical development activities. GenVec release

> Forest Laboratories has responded to the FDA's request for more information on COPD drug Daxas, which was rejected by an expert panel earlier this year. The agency didn't ask for any new trials of the drug. News

> A shareholder is suing Acura Pharmaceuticals following the FDA rejection of the company's painkiller Acurox. The shareholder claims CEO Andrew Reddick, among others, made misleading statements about the drug's clinical trial performance. Report

And Finally... Don't get enough sleep? A new study finds you could be at risk of dying prematurely. Report

Suggested Articles

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.

The Big Pharma paid $134 million to enter into the two partnerships, but then dropped the projects after Voyager completed research activities. 

Combining a vaccine targeting HER2D16 with a PD-1 inhibitor improved tumor regression in mice with HER2-positive breast cancer.